- Home
- SNDX vs BCSF Comparison
SNDX vs BCSF Comparison
Compare SNDX & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- BCSF
- Stock Information
- Founded
- SNDX 2005
- BCSF 2015
- Country
- SNDX United States
- BCSF United States
- Employees
- SNDX N/A
- BCSF N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- SNDX Health Care
- BCSF Finance
- Exchange
- SNDX Nasdaq
- BCSF Nasdaq
- Market Cap
- SNDX 1.1B
- BCSF 1.1B
- IPO Year
- SNDX 2016
- BCSF 2018
- Fundamental
- Price
- SNDX $13.67
- BCSF $17.73
- Analyst Decision
- SNDX Strong Buy
- BCSF Hold
- Analyst Count
- SNDX 10
- BCSF 4
- Target Price
- SNDX $36.20
- BCSF $16.75
- AVG Volume (30 Days)
- SNDX 2.6M
- BCSF 194.2K
- Earning Date
- SNDX 02-25-2025
- BCSF 02-25-2025
- Dividend Yield
- SNDX N/A
- BCSF 10.19%
- EPS Growth
- SNDX N/A
- BCSF N/A
- EPS
- SNDX N/A
- BCSF 1.99
- Revenue
- SNDX $16,000,000.00
- BCSF $294,257,000.00
- Revenue This Year
- SNDX N/A
- BCSF N/A
- Revenue Next Year
- SNDX N/A
- BCSF N/A
- P/E Ratio
- SNDX N/A
- BCSF $8.91
- Revenue Growth
- SNDX N/A
- BCSF 3.17
- 52 Week Low
- SNDX $12.06
- BCSF $14.78
- 52 Week High
- SNDX $25.34
- BCSF $17.97
- Technical
- Relative Strength Index (RSI)
- SNDX 48.26
- BCSF 62.28
- Support Level
- SNDX $12.40
- BCSF $16.79
- Resistance Level
- SNDX $13.16
- BCSF $17.58
- Average True Range (ATR)
- SNDX 0.66
- BCSF 0.29
- MACD
- SNDX 0.14
- BCSF 0.01
- Stochastic Oscillator
- SNDX 62.16
- BCSF 79.66
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.